JP2013529916A5 - - Google Patents

Download PDF

Info

Publication number
JP2013529916A5
JP2013529916A5 JP2013514731A JP2013514731A JP2013529916A5 JP 2013529916 A5 JP2013529916 A5 JP 2013529916A5 JP 2013514731 A JP2013514731 A JP 2013514731A JP 2013514731 A JP2013514731 A JP 2013514731A JP 2013529916 A5 JP2013529916 A5 JP 2013529916A5
Authority
JP
Japan
Prior art keywords
seq
excluded
peptide
amino acid
peptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013514731A
Other languages
English (en)
Japanese (ja)
Other versions
JP5709985B2 (ja
JP2013529916A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/060105 external-priority patent/WO2011157819A2/en
Publication of JP2013529916A publication Critical patent/JP2013529916A/ja
Publication of JP2013529916A5 publication Critical patent/JP2013529916A5/ja
Application granted granted Critical
Publication of JP5709985B2 publication Critical patent/JP5709985B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013514731A 2010-06-18 2011-06-17 生体バリアを安定化させる活性剤としてのペプチド Expired - Fee Related JP5709985B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA1010/2010 2010-06-18
AT10102010 2010-06-18
PCT/EP2011/060105 WO2011157819A2 (en) 2010-06-18 2011-06-17 Peptides as active agents to stabilize biological barriers

Publications (3)

Publication Number Publication Date
JP2013529916A JP2013529916A (ja) 2013-07-25
JP2013529916A5 true JP2013529916A5 (enExample) 2014-06-26
JP5709985B2 JP5709985B2 (ja) 2015-04-30

Family

ID=44628513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013514731A Expired - Fee Related JP5709985B2 (ja) 2010-06-18 2011-06-17 生体バリアを安定化させる活性剤としてのペプチド

Country Status (8)

Country Link
US (1) US9012403B2 (enExample)
EP (1) EP2582720B1 (enExample)
JP (1) JP5709985B2 (enExample)
CN (1) CN103038253A (enExample)
CA (1) CA2802635A1 (enExample)
ES (1) ES2486321T3 (enExample)
RU (1) RU2012157399A (enExample)
WO (1) WO2011157819A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3459558B1 (en) 2010-06-25 2020-07-29 Aston University Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
NL2015130B1 (en) * 2015-07-09 2017-02-01 Mimetas B V Barrier function measurements.
AU2017244108B2 (en) * 2016-03-29 2021-03-18 University Of Southern California Chimeric antigen receptors targeting cancer
JP7483684B2 (ja) * 2018-08-17 2024-05-15 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 急性肺損傷の処置のための組成物および方法
JP7486497B2 (ja) * 2019-01-16 2024-05-17 ユニバーシティ オブ ロチェスター 上皮または内皮バリア機能の改善
EP4093423A1 (en) 2020-01-22 2022-11-30 UCL Business Ltd Peptide inhibitors of guanine nucleotide exchange factor-h1

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US20040053250A1 (en) 2001-03-05 2004-03-18 Tang Y. Tom Novel arginine-rich protein-like nucleic acids and polypeptides
ATE424416T1 (de) * 2002-07-03 2009-03-15 San Raffaele Centro Fond Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
DE602008005596D1 (de) 2007-06-21 2011-04-28 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität

Similar Documents

Publication Publication Date Title
JP2013529916A5 (enExample)
JP2015517489A5 (enExample)
Klos et al. International union of basic and clinical pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors
JP2016222689A5 (ja) 合成ペプチド及び乾燥粉末薬剤輸送システム
JP2012115277A5 (enExample)
JP2016521688A5 (enExample)
JP2015533791A5 (enExample)
JP2012126742A5 (enExample)
JP2020023567A5 (enExample)
JP2015522576A5 (enExample)
JP2015134758A5 (enExample)
JP2015517488A5 (enExample)
JP2013539454A5 (enExample)
JP2013505286A5 (enExample)
JP2015513318A5 (enExample)
JP2014527040A5 (enExample)
JP2015057436A5 (enExample)
HRP20201081T1 (hr) Inhibitorni peptidi porijeklom od trem-sličnog transkripta 1 (tlt-1) i njihove uporabe
JP2011137005A5 (enExample)
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
WO2014151200A3 (en) Guanylate cyclase receptor agonists combined with other drugs
JP2015522264A5 (enExample)
ECSP22016180A (es) Proteínas de fusión terapéuticas
HRP20200875T1 (hr) Inhibitorni peptidi porijeklom od aktivirajućeg receptora eksprimiranog na mijeloidnim stanicama-1 (trem-1)-sličnog transkripta 1 (tlt-1) i nihove upotrebe
RU2012157399A (ru) Пептиды в качестве активных агентов для стабилизации биологических барьеров